Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | STS | P08842 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422179 | 0.92 | HSD17B3 (0.71) | HSD17B3HTR7STSL3MBTL1THRA | |
| SCHEMBL14522305 | 0.89 | HSD17B3 (0.83) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL19757443 | 0.88 | HSD17B3 (0.65) | HSD17B3HTR7STSL3MBTL1THRA | |
| SCHEMBL319591 | 0.88 | HSD17B3 (0.67) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL13670607 | 0.85 | L3MBTL1 (0.61) | HSD17B3L3MBTL1NPC1RAB9A | |
| SCHEMBL5306901 | 0.83 | NPC1 (0.54) | HSD17B3HTR7L3MBTL1NPC1RAB9A | |
| SCHEMBL11661975 | 0.83 | HSD17B3 (0.74) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL18753070 | 0.83 | HSD17B3 (0.84) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL5456494 | 0.82 | HSD17B3 (0.71) | HSD17B3HTR7STSL3MBTL1HPGD | |
| SCHEMBL5306907 | 0.82 | NPC1 (0.52) | HSD17B3HTR7L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | SLC6A2, SLC6A4, SLC6A3 | HSD17B3 225/4885HTR7 130/4885STS 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.